In general, the recommended use of ponatinib is 45 mg orally once daily. For patients with concomitant risk factors, an initial dose starting at 30mg may be a safer and more effective dose. The use of this medication needs to be under the supervision of a physician. The first step is to clarify eligibility for the drug, which includes two conditions: patients with lymphoma and who have received at least one prior therapy; and adult patients with chronic lymphocytic leukemia who are refractory to or intolerant of prior tyrosine kinase inhibitor therapy. Once eligible, the medication can be administered under the supervision of a physician. The recommended dose of ponatinib is 45 mg orally once daily with or without food until disease progression or intolerant toxicities occur. For patients with concomitant risk factors, an initial dose starting at 30mg may be a safer and more effective dose.